mining the market

Investors + news

We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.

see our business strategy in action

Eagle Pharmaceuticals 2020 Annual Report

Investors Menu


Featured Press Release

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as
See More
Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income * was $4.10 per basic and $4.04 per diluted share Q1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021 Achieved sales of $34.3 million of vasopressin, with prior four weeks
See More
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.
See More

Upcoming Events & Presentations

Change % Volume Data as of 04/15/2022 1:08 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

Communications, Inc.
Lisa M. Wilson,

For all other media inquiries, please contact us.